NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.28 billion biopharmaceutical company with impressive 51% revenue ...

"We are delighted to welcome these distinguished scientists and clinicians to our Scientific Advisory Board," said Dr. Neal Walker, Interim CEO and Chair of the Board of Directors of Aclaris ...

Q4 2024 Management View CEO Gilles Martin highlighted significant progress in the company's hub-and-spoke lab network and IT ...

Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is ...

Global biopharmaceutical manufacturing firm Rentschler Biopharma will shutter its United Kingdom facility as the ...

Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic branded formulation ...

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations as part of ...

Zenas BioPharma, Inc.’s ZBIO share price has surged by 13.37%, which has investors questioning if this is right time to sell.

From a margin perspective, Danaher's operations should eventually improve once top-line growth rebounds. With that operating leverage-related margin expansion, we expect Danaher's adjusted EPS to grow ...

We recently published a list of 10 AI News And Ratings on Wall Street’s Radar. In this article, we are going to take a look ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...